Beta talasemija intermedia i minor (pedijatrija)
Farmakološka indukcija sinteze fetalnog hemoglobina
Terapija (hidroksikarabamidom) hidroksiureom
Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (otvara novi prozor)
Izvor: Hemoglobin 2014;38(1):44-8.
Indeks: PubMed 24144212
DOI: 10.3109/03630269.2013.845844
https://www.ncbi.nlm.nih.gov/pubmed/24144212 (otvara novi prozor)
Hydroxyurea in thalassemia intermedia--a promising therapy. (otvara novi prozor)
Izvor: Ann Hematol 2005;84(7):441-6.
Indeks: PubMed 15838670
DOI: 10.1007/s00277-005-1026-4
https://www.ncbi.nlm.nih.gov/pubmed/15838670 (otvara novi prozor)
Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (otvara novi prozor)
Izvor: J Clin Pathol 2010;63(2):147-50.
Indeks: PubMed 20154037
DOI: 10.1136/jcp.2009.070391
https://www.ncbi.nlm.nih.gov/pubmed/20154037 (otvara novi prozor)
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (otvara novi prozor)
Izvor: Eur J Haematol 2009;82(3):213-8.
Indeks: PubMed 19077048
DOI: 10.1111/j.1600-0609.2008.01192.x
https://www.ncbi.nlm.nih.gov/pubmed/19077048 (otvara novi prozor)
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. (otvara novi prozor)
Izvor: J Pediatr Hematol Oncol 2005;27(7):380-5.
Indeks: PubMed 16012328
https://www.ncbi.nlm.nih.gov/pubmed/16012328 (otvara novi prozor)
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (otvara novi prozor)
Izvor: Eur J Haematol 2010;84(1):52-8.
Indeks: PubMed 19799627
DOI: 10.1111/j.1600-0609.2009.01356.x
https://www.ncbi.nlm.nih.gov/pubmed/19799627 (otvara novi prozor)
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. (otvara novi prozor)
Izvor: Pediatr Hematol Oncol 2003;20(6):429-34.
Indeks: PubMed 14631615
https://www.ncbi.nlm.nih.gov/pubmed/14631615 (otvara novi prozor)
Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (otvara novi prozor)
Izvor: Ann N Y Acad Sci 2005;1054:250-6.
Indeks: PubMed 16339672
DOI: 10.1196/annals.1345.031
https://www.ncbi.nlm.nih.gov/pubmed/16339672 (otvara novi prozor)
Rekombinovani eritropoetin (sam ili u kombinaciji sa drugim lekovima)
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (otvara novi prozor)
Izvor: Acta Haematol 2004;111(4):189-95.
Indeks: PubMed 15153710
DOI: 10.1159/000077551
https://www.ncbi.nlm.nih.gov/pubmed/15153710 (otvara novi prozor)
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. (otvara novi prozor)
Izvor: Eur J Haematol 2013;91(6):522-33.
Indeks: PubMed 23927461
DOI: 10.1111/ejh.12182
https://www.ncbi.nlm.nih.gov/pubmed/23927461 (otvara novi prozor)
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (otvara novi prozor)
Izvor: Pediatr Ann 2008;37(5):339-46.
Indeks: PubMed 18543545
https://www.ncbi.nlm.nih.gov/pubmed/18543545 (otvara novi prozor)
Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. (otvara novi prozor)
Izvor: Br J Haematol 1995;90(2):341-5.
Indeks: PubMed 7794754
https://www.ncbi.nlm.nih.gov/pubmed/7794754 (otvara novi prozor)
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (otvara novi prozor)
Izvor: Br J Haematol 2011;154(2):281-4.
Indeks: PubMed 21496003
DOI: 10.1111/j.1365-2141.2011.08617.x
https://www.ncbi.nlm.nih.gov/pubmed/21496003 (otvara novi prozor)
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (otvara novi prozor)
Izvor: Blood Rev 2012;26 Suppl 1:S35-9.
Indeks: PubMed 22631042
DOI: 10.1016/S0268-960X(12)70011-5
https://www.ncbi.nlm.nih.gov/pubmed/22631042 (otvara novi prozor)
Drugi lekovi
Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. (otvara novi prozor)
Izvor: Evid Based Complement Alternat Med 2009;6(2):141-51.
Indeks: PubMed 18955291
DOI: 10.1093/ecam/nem139
https://www.ncbi.nlm.nih.gov/pubmed/18955291 (otvara novi prozor)
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. (otvara novi prozor)
Izvor: Br J Haematol 2013;161(4):587-93.
Indeks: PubMed 23530969
DOI: 10.1111/bjh.12304
https://www.ncbi.nlm.nih.gov/pubmed/23530969 (otvara novi prozor)
Butyric acid: what is the future for this old substance? (otvara novi prozor)
Izvor: Swiss Med Wkly 2012;142:w13596.
Indeks: PubMed 22674349
DOI: 10.4414/smw.2012.13596
https://www.ncbi.nlm.nih.gov/pubmed/22674349 (otvara novi prozor)